Navigation Links
UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
Date:10/17/2009

excluding non-melanoma skin cancer) were observed at a rate of 0.5 per 100 patient-years among 4,650 Cimzia®-treated patients versus a rate of 0.6 per 100 patient-years among 1,319 placebo-treated patients. In studies of Cimzia® for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 Cimzia®-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In Cimzia® RA clinical trials (placebo-controlled and open label) a total of three cases of lymphoma were observed among 2,367 patients. This is approximately 2-fold higher than expected in the general population. Patients with RA, particularly those with highly active disease, are at a higher risk for the development of lymphoma. The potential role of TNF blocker therapy in the development of malignancies is not known.

Heart Failure

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Cimzia® has not been formally studied in patients with CHF. Exercise caution when using Cimzia® in patients who have heart failure and monitor them carefully.

Hypersensitivity

Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following Cimzia® administration. If such reactions occur, discontinue further administration of Cimzia® and institute appropriate therapy.

Hepatitis B Reactivation

Use of TNF blockers, including Cimzia®, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating Cimzia® therapy. Exercise caution in pre
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohns Patients
2. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
3. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
4. Tiny test tube experiment shows reaction of melting materials at the nano scale
5. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
6. Topical erectile dysfunction therapy shows promise
7. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost
8. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
9. Video shows nanotube spins as it grows
10. MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
11. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. ... cancers, today announced that Linda Powers , NW Bio CEO, ... vaccine platform for solid tumor cancers and the Company,s multiple ...   , , , DATE: , , , ... , , , 12:15 PM EDT , , , ...
(Date:5/6/2015)... May 06, 2015 Park Systems ... NX-Hivac, the only high vacuum AFM system in the ... failure analysis semiconductor manufacturing. Park NX-Hivac is ideal for ... analysis solutions in highly doped semiconductor processing where more ... , The high vacuum scanning spreading resistance microscopy (SSRM) ...
(Date:5/6/2015)... Histogen, Inc., a regenerative medicine company ... grown under simulated embryonic conditions, will present new ... melanoma during the 2015 Society of Investigative Dermatology ... in Atlanta, GA. , Histogen has previously shown ... with anti-oncologic properties, with potential benefit in the ...
(Date:5/6/2015)... 06, 2015 The Remedy Group ... strategy for the specialty pharmacy industry, will be exhibiting, ... Armada Specialty Pharmacy Summit. The Summit will be held ... Vegas and is the largest annual gathering for the ... attendance, from pharmacy providers, pharma/biotech manufacturers, and payers, to ...
Breaking Biology Technology:NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2
... Corp. (TSX: HBP / Frankfurt: WKN 918864), ... Corp.,announces that at the Company,s Annual General Meeting ... the resolutions presented by,management, appointing KPMG LLP as ... Kay, Slawomir Majewski, and Gordon Lickrish as,directors, and ...
... Jan. 30 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ... novel anti-infective products, today,announced that it has closed ... warrants, resulting in the receipt of $21 million ... the proceeds from the financing to support,the manufacture ...
... Jan. 30 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... bio-enhanced feed products sold during the fourth,quarter of ... and increased,25% over the same period in the ... ("Kiwa Tianjin") is a joint-venture of Kiwa,and Tianjin ...
Cached Biology Technology:Helix BioPharma shareholders vote in favour of management 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 3Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007 2
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... -- Rice University scientists have unveiled a revolutionary new ... into steam. The new "solar steam" method from Rice,s ... even produce steam from icy cold water. Details ... in ACS Nano . The technology has an ...
... after Hurricane Sandy hit, NJIT Professor Michel Boufadel was awarded ... of the storm on the New Jersey shoreline. The ... a team of eight researchers to the beaches of Raritan ... students is still fanning out over the shoreline and ...
... getting, when they select females for mating, according to a ... Wisconsin-Milwaukee in the US. His work, which is one of ... mating behaviors in a nocturnal anuran (frog or toad), is ... . Animals display a number of courtship behaviors and ...
Cached Biology News:Rice unveils super-efficient solar-energy technology 2Rice unveils super-efficient solar-energy technology 3NJIT civil engineer receives NSF grant to study storm's impact on Jersey Shore 2Vision stimulates courtship calls in the grey tree frog 2
... Cultures (ECACC) in conjunction with the Univeristy ... England, Bristol, UK, have produced standardised cell ... oestrogen and progresterone receptor assays. The slides ... fixed, breast cancer cell lines; MDA-MD-361, T47D, ...
kismet (dK-20)...
... potent TURBO DNase (patent pending) in the TURBO ... DNA removal capabilities. TURBO DNase is a recombinant, ... more efficient than wild type DNase I in ... DNase binds DNA substrates 6-fold more tightly than ...
...
Biology Products: